
Accepted Manuscript

Title: How to escape the cancer attractor: rationale and limitations of multi-target drugs

Author: Sui Huang Stuart Kauffman



| PII: | S1044-579X(13)00054-0 |
|----------------|-------------------------------------------------------|
| DOI: | http://dx.doi.org/doi:10.1016/j.semcancer.2013.06.003 |
| Reference: | YSCBI 1054 |
| To appear in: | Seminars in Cancer Biology |
| Received date: | 20-5-2013 |
| Revised date: | 12-6-2013 |
| Accepted date: | 13-6-2013 |

Please cite this article as: Huang S, Kauffman S, HOW TO ESCAPE THE CANCER ATTRACTOR: RATIONALE AND LIMITATIONS OF MULTI-TARGET DRUGS, *Seminars in Cancer Biology* (2013), http://dx.doi.org/10.1016/j.semcancer.2013.06.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

REVISED - 2013

HOW TO ESCAPE THE CANCER ATTRACTOR: RATIONALE AND LIMITATIONS OF MULTI-TARGET DRUGS

Sui Huang^{1,2} and Stuart Kauffman^{2,3}

¹ Institute for Systems Biology

² Institute for Biocomplexity and Informatics, University of Calgary

³ College of Medicine, Biochemistry & CEMS, Department of Mathematics & Statistics, University of Vermont

Contact: sui.huang@systemsbiology.org

ABSTRACT

The increasingly evident limitations of target-selective cancer therapy has stimulated a flurry of ideas for overcoming the development of resistance and recurrence – the near universal reason for therapy failure from which target-selective drugs are not exempt. A widely proposed approach to conquer therapy resistance is to depart from the myopic focus on individual causal pathways and instead target multiple nodes in the cancer cell's gene regulatory network. However, most ideas rely on a simplistic conceptualization of networks: utilizing solely their topology and treating it as a display of causal interactions, while ignoring the integrated dynamics in state space. Here we review the more encompassing formal framework of global network dynamics in which cancer cells, like normal cell types, are high-dimensional attractor states. Then therapy is represented by the network perturbation that will promote the exit from such cancer attractors and reentering a normal attractor. We show in this qualitative and accessible discussion how the idea of a quasi-potential landscape and the theory of least-action-path offer a new formal understanding for computing the set of network nodes (molecular targets) that need to be targeted in concert in order to exit the cancer attractor. But targeting cancer cells based on the network configuration of an "average" cancer cell, however precise, may not suffice to eradicate all tumor cells because of the dynamic non-genetic heterogeneity of cancer cell populations that makes them moving targets and drives the replenishment of the cancer attractor with surviving, non-responsive cells from neighboring abnormal attractors.

1. INTRODUCTION

The near universal failure of target-selective anti-cancer drugs [1] designed to block a mitogenic or survival pathway has revived an old idea: to use either combination therapy or multi-target drugs (polypharmacology) [2, 3] to conquer the cancer cells' unfathomable capacity of resilience and resistance. But what is new? Combination therapy has of course been in use since the dawn of chemotherapy – motivated by clinical reasoning [4]. But the increasing availability of pathway information, which has brought us the target-selective drugs, and burgeoning "systems biology" thinking in drug discovery [5, 6] have led to a new climate of multi-dimensional mechanistic reasoning. One central idea is that by attacking multiple pathways at once one could prevent the utilization of alternative survival pathways that allows cells to evade the therapy (for recent review, see [7, 8]).

Download English Version:

https://daneshyari.com/en/article/10845625

Download Persian Version:

https://daneshyari.com/article/10845625

Daneshyari.com